| Literature DB >> 34675940 |
Zhending Gan1, Meiyu Zhang2, Donghui Xie3, Xiaoyan Wu1,4, Changming Hong1, Jian Fu1, Lijuan Fan1, Shengyi Wang4, Sufang Han1.
Abstract
Accumulating evidences support that amino acids direct the fate decision of immune cells. Glycine is a simple structural amino acid acting as an inhibitory neurotransmitter. Besides, glycine receptors as well as glycine transporters are found in macrophages, indicating that glycine alters the functions of macrophages besides as an inhibitory neurotransmitter. Mechanistically, glycine shapes macrophage polarization via cellular signaling pathways (e.g., NF-κB, NRF2, and Akt) and microRNAs. Moreover, glycine has beneficial effects in preventing and/or treating macrophage-associated diseases such as colitis, NAFLD and ischemia-reperfusion injury. Collectively, this review highlights the conceivable role of glycinergic signaling for macrophage polarization and indicates the potential application of glycine supplementation as an adjuvant therapy in macrophage-associated diseases.Entities:
Keywords: NF-κB; glycine; inflammation; macrophage; miRNA
Mesh:
Substances:
Year: 2021 PMID: 34675940 PMCID: PMC8523992 DOI: 10.3389/fimmu.2021.762564
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Neutral-amino-acid transporters which transport glycine.
| System | Gene | Transporters (Full name and abbreviation) |
|---|---|---|
|
| ||
|
| SLC38A1 | Serine acetyltransferase 1 (SAT1) |
| SLC38A2 | SAT2 | |
| SLC38A4 | SAT3 | |
|
| SLC6A9 | Glycine transporter 1 (GlyT1) |
| SLC6A5 | GlyT2 | |
|
| ||
|
| SLC7A10 | Asc Type Amino Acid Transporter 1/2 (ASC1/2) |
|
| SLC36A1 | Proton-coupled amino acid transporter 1 (PAT1) |
| SLC36A2 | Proton-coupled amino acid transporter 2 (PAT2) | |
Figure 1Probable cellular pathways that glycine influences M1 macrophages polarization. (A) Glycine inhibits the degradation of IκB in M1-macrophages. (B) Glycine inhibits M1-macrophages polarization via inhibiting IKK phosphorylation. (C) Glycine up-regulates NRF-2/HO-1 to blunt NLRP3 in inflammasome in M1-macrophages. (D) Glycine inhibits NF-κB by blocking PTEN to up-regulate Akt in M1-macrophages. LPS, lipopolysaccharide; TLR4, toll-like receptor 4; MyD88, myeloid differentiation primary response gene 88; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IκB, inhibitor of NF-κB; IKK, IκB kinase; TNF-α, tumor necrosis alpha; TNFR, TNF-α receptor; TRAF, TNFR associated factor; PTEN, phosphatase and tensin homolog deleted on chromosome ten; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; Akt, protein kinase B.
Figure 2Glycine shapes macrophage polarization through micro-RNAs. (A) Glycine up-regulates miR-26b to blunt M1-microglia polarization by suppressing PTEN and activating Akt. (B) Glycine possibly up-regulates miR-301a to promote M2-macrophages polarization via activating PI3K/Akt. (C, D) Glycine down-regulates miR-19a-3p. (C) MiR-19a-3p negatively control STAT1 and AMPK to blunt M1-macrophages polarization. (D) MiR-19a-3p negatively control STAT3 to inhibit M2 macrophage polarization. (E) MiR-96 and miR-137 negatively regulate GlyT1. PTEN, phosphatase and tensin homolog deleted on chromosome ten; Akt, protein kinase B; STAT, signal transducer and activator of transcription; GlyT, glycine transporter.
Beneficial effects of glycine in other macrophage-associated diseases.
| Model | Dose | Features | References |
|---|---|---|---|
|
| Dietary supplementation with 5% glycine | Pro-inflammatory cytokines ↓ | ( |
|
| Intravenous injection of 100/300 mmol glycine | Pathological structure ↑; Pro-inflammatory cytokines ↓ | ( |
| MPO activity ↓ | |||
|
| 5mM glycine supplemented in culture medium | Pro-inflammatory interleukin level ↓ | ( |
| Nf-κB activation ↓ | |||
|
| Dietary supplementation with 5% glycine | Survival rate ↑, | ( |
| Serum pro-inflammatory cytokines level ↓ | |||
|
| Dietary supplementation with 5% glycine | Macroscopic and histologic scores ↑ | ( |
↑, increase/up-regulate; ↓, decrease/down-regulate.